← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIGOUT PREPARATIONS › ANTIGOUT PREPARATIONS › Preparations increasing uric acid excretion
sulfinpyrazone
M04AB02
Forms & Strengths
- Oral tablets: 100 mg
- Oral capsules: 200 mg
Adult Dosing
- Initial: 100 to 200 mg orally twice daily with meals or antacids for one week
- Maintenance: 200 to 400 mg orally twice daily
- Maximum dose: 800 mg daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of chronic and intermittent gouty arthritis
Mechanism of Action
- Potent uricosuric agent that inhibits the renal tubular reabsorption of uric acid
- Increases urinary excretion of uric acid and lowers serum urate levels
- Possesses platelet aggregation inhibitory properties
Contraindications
- Known hypersensitivity to sulfinpyrazone or other pyrazolone derivatives
- Active peptic ulcer disease
- History of severe blood dyscrasias
- Significant renal impairment (creatinine clearance < 30 mL/min)
Adverse Reactions
- Gastrointestinal distress, nausea, vomiting, dyspepsia, reactivation of peptic ulcer
- Hypersensitivity reactions including rash, urticaria, and dermatitis
- Hematologic effects including leukopenia, thrombocytopenia, anemia, and aplastic anemia
- Nephrolithiasis and acute uric acid nephropathy due to increased urate excretion
Drug Interactions
- Salicylates (e.g., aspirin) diminish the uricosuric effect of sulfinpyrazone and should be avoided
- Enhances the hypoglycemic effect of oral sulfonylureas
- Increases the anticoagulant effect of warfarin and other coumarin derivatives
- Decreases the renal clearance of lithium, potentially leading to lithium toxicity
Curated Content: Needs Vetting Before Put to Clinical Use